NCT04644211View on ClinicalTrials.gov

Ruxolitinib in Thrombocythemia and Polycythemia Vera

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2034

Conditions
Essential ThrombocythemiaPolycythemia Vera
Interventions
DRUG

Ruxolitinib

Pill taken by mouth.

Trial Locations (4)

02115

RECRUITING

Massachusetts General Hospital, Boston

02215

NOT_YET_RECRUITING

Beth-Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

01923

RECRUITING

Massachusetts General North Shore Cancer Center, Danvers

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Massachusetts General Hospital

OTHER